Arbutus Biopharma Corp
ABUS | NASDAQ
$5.01
+$0.01 (+0.20%)
Sep 22, 2026, 11:34 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 153.05M | 160.72M | -33.5M | -42.28M | -54.25M | -76.57M | -69.92M | -76.7M | -77.09M | -74.39M | -72.85M | -75.47M | -72.93M | -70.03M | -69.46M | -68.85M | -70.44M | -75.63M | -76.25M | -71.97M | -71.57M | -66.27M |
Depreciation & Amortization | 44K | 44K | 363K | 685K | 1.01M | 1.36M | 1.38M | 1.41M | 1.44M | 1.43M | 1.4M | 1.35M | 1.33M | 1.37M | 1.43M | 1.55M | 1.65M | 1.7M | 1.75M | 1.81M | 1.86M | 1.92M |
Stock-Based Compensation | 5.51M | 4.75M | 6.95M | 7.32M | 8.22M | 10.54M | 8.99M | 9.08M | 9.4M | 9.18M | 9.3M | 9.25M | 8.48M | 7.58M | 7.18M | 6.95M | 6.85M | 6.53M | 6.42M | 6.42M | 6.5M | 6.35M |
Other Working Capital | -176.61M | -194.48M | -15.94M | -17.3M | -20.99M | -203K | -172K | 348K | -819K | -6.41M | -10.59M | -8.65M | -6.15M | -13.66M | 28.24M | 25.45M | 27.03M | 38.16M | -68K | -1.37M | -1.57M | 674K |
Other Non-Cash Items | -6.06M | -6.69M | -3.43M | 1.05M | 530K | 435K | -2.47M | -4.5M | -4.63M | -5.4M | -5.56M | -4.56M | -5.19M | -4.36M | -3.75M | -4.6M | -2.8M | -1.27M | -633K | 351K | 3.41M | 3.38M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 241K | 241K | 241K | 241K | n/a | n/a | n/a |
Change in Working Capital | -177.17M | -193.17M | -10.02M | -12.05M | -15.7M | 5.3M | -2.83M | -1.11M | -2M | -8.76M | -18.23M | -16.21M | -14.22M | -17.83M | 29.24M | 26.74M | 29.19M | 39.39M | 930K | 441K | 724K | 749K |
Operating Cash Flow | -24.62M | -34.36M | -39.64M | -45.27M | -60.19M | -58.95M | -64.85M | -71.83M | -72.88M | -77.93M | -85.94M | -85.63M | -82.54M | -83.28M | -35.36M | -37.97M | -35.32M | -29.03M | -67.53M | -62.94M | -59.08M | -53.87M |
Capital Expenditures | n/a | n/a | n/a | -86K | -86.41K | -87.41K | -182.41K | -83.75K | -115.34K | -973.34K | -995.34K | -1.14M | -1.2M | -554K | -512K | -436K | -365K | -785K | -809K | -903K | -894K | -328K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | 37.19M | 37.19M | 37.19M | 37.19M | 37M | 37M | 37M | 37M | n/a | 1.81M | 1.81M | 1.81M | 1.81M | n/a | n/a | n/a |
Purchase of Investments | -114.31M | -119.15M | -140.06M | -157.71M | -146.74M | -150.83M | -141.51M | -122.34M | -89.09M | -85.7M | -80.51M | -69.65M | -95.22M | -88.65M | -130.43M | -145.33M | -112.69M | -142.17M | -82.22M | -110.83M | -113.81M | -63.24M |
Sales Maturities Of Investments | 103.11M | 125.21M | 155.28M | 188.13M | 175.2M | 173.52M | 164.64M | 154.2M | 143.37M | 132.46M | 132.27M | 112.03M | 113.5M | 91M | 56M | 50M | 47M | 52M | 70.35M | 57.2M | 60.8M | 71.78M |
Other Investing Acitivies | 355K | 354K | 355K | n/a | n/a | n/a | -37.19M | -37.19M | -37.17M | -37.17M | -36.98M | -37M | -37.02M | -37M | n/a | -1.79M | -1.79M | -1.81M | -1.81M | n/a | -2.5M | -2.5M |
Investing Cash Flow | -10.84M | 6.43M | 15.58M | 30.35M | 28.39M | 22.6M | 22.95M | 31.76M | 54.18M | 45.79M | 50.77M | 41.23M | 17.06M | 1.79M | -74.94M | -95.75M | -66.04M | -90.96M | -12.68M | -54.53M | -56.41M | 5.71M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -12.14M | -12.14M | -12.14M | -12.14M | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | 1.42M | 1.42M | 3.43M | 6.1M | 4.63M | 4.92M | 2.91M | 795K | 841K | 715K | 828K | 11.49M | 23.51M | 25.57M | 25.47M | 14.71M | 2.72M | 839K | 738K |
Financial Cash Flow | 17.25M | 14.56M | 5.72M | 5.5M | 6.43M | 30.35M | 52M | 54.38M | 54.29M | 34.66M | 30.65M | 37.92M | 45.38M | 40.75M | 31.81M | 79.85M | 117.67M | 121.85M | 137.24M | 98.33M | 100.47M | 101.14M |
Net Cash Flow | -18.24M | -13.37M | -18.32M | -9.44M | -25.38M | -6.03M | 10.05M | 14.32M | 35.59M | 2.53M | -4.49M | -6.47M | -20.12M | -40.76M | -78.51M | -53.88M | 16.37M | 1.91M | 57.03M | -19.04M | -14.95M | 53.01M |
Free Cash Flow | -24.63M | -34.36M | -39.64M | -45.36M | -60.28M | -59.03M | -65.03M | -71.92M | -73M | -78.92M | -86.94M | -86.78M | -83.74M | -83.83M | -35.87M | -38.41M | -35.68M | -29.82M | -68.34M | -63.84M | -59.97M | -54.2M |
Adj. Free Cash Flow | -30.13M | -39.1M | -46.59M | -52.68M | -68.5M | -69.57M | -74.02M | -81M | -82.4M | -88.1M | -96.25M | -96.02M | -92.22M | -91.41M | -43.05M | -45.35M | -42.53M | -36.34M | -74.77M | -70.27M | -66.47M | -60.55M |
Maintenance CapEx | n/a | n/a | n/a | -86K | -86.41K | -87.41K | -182.41K | -83.75K | -115.34K | -973.34K | -995.34K | -1.01M | -976K | -117K | n/a | n/a | n/a | n/a | n/a | n/a | -11K | -11K |
Growth CapEx | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -134K | -225K | -437K | -512K | -436K | -365K | -785K | -809K | -903K | -883K | -317K |
Owner Earnings | -24.63M | -34.36M | -39.64M | -45.36M | -60.28M | -59.03M | -65.03M | -71.91M | -72.99M | -78.9M | -86.93M | -86.64M | -83.52M | -83.39M | -35.36M | -37.97M | -35.32M | -29.03M | -67.53M | -62.94M | -59.09M | -53.88M |
Add to Watchlist
Select watchlists to add or remove ABUS